TRANSCRIPT: Hello, my name is Andrea. Alms. I am a technology investor and financial manager and this is your money in motion. The future of pediatric rare disease is in question. The end. The U.S. Congress did not reauthorize the Rare Disease Priority Review Program at the end of 2024, despite bipartisan support. Advocates felt the ripple effect is being felt now across biopharma.
Rare disease. Pediatric disease has historically been overlooked in drug development, as pharmaceutical c